Biogen, Genentech appeal Arzerra ruling for GSK; Ranbaxy launches copy of Pfizer's Caduet;

FiercePharma: FDA weighs Teva's request to bring Plan B contraceptive out from behind the pharmacists' counter. News | Follow @FiercePharma

> Roche's Genentech unit and Biogen Idec ($BIIB) are appealing a judgment in favor of GlaxoSmithKline ($GSK) in a patent fight over the blood cancer drug Arzerra. Report

> Ranbaxy Laboratories has launched its generic version of Pfizer's ($PFE) blood-pressure drug Caduet in the U.S. News

> GlaxoSmithKline ($GSK) has nabbed one necessary approval for its offshore wind-turbine site near Montrose in Scotland. Item

> Ex-NFL players are suing the league and its teams, saying they were given the blood-thinning painkiller Toradol before and during games, worsening injuries such as concussions. Story

> India's Elder Pharmaceuticals is poised to jump into the Japanese market, armed with regulatory approval for its API plant in Patalganga. Piece

> Cobb County, GA gave Osmotica Pharmaceutical a $564,539 tax break in exchange for creating 144 jobs at a former Solvay Pharmaceuticals site. More

> Asahi Kasei Pharma launched its subcutaneous injectable form of Teribone, an osteoporosis remedy, in Japan. Report 

Biotech News

@FierceBiotech: Biogen Idec signs up with Samsung on $300 million biosimilars venture. News | Follow @FierceBiotech

@JohnCFierce: Sustained release levodopa/carbidopa (xenoport) fails Ph2 Parkinson's study. Does anyone really understand this field? Report | Follow @JohnCFierce

@RyanMFierce: Sanofi's GLP-1 drug yields upbeat data in pivotal study in T2DM. GLP-1 class growing beyond Byetta/Bydureon, Victoza. Item | Follow @RyanMFierce

@FierceMedDev: Randox's new molecular diagnostic test permits quick selection of colorectal cancer patients for Anti-EGFR therapy. Release | Follow @FierceMedDev

> Merck blueprints Asian R&D HQ in Beijing in $1.5B research blitz. News

Biotech Research News

> Partial, lab-grown pituitary gland works in mice. News

> Gene may hold back skin, head, neck cancers. Story

> Researchers unmask protein as villain in pancreatic, brain cancer growth. Item

> Search is on for new anti-addiction drug targets. Article

> Adult stem cell pathway could yield better muscle disorder treatments. Report

Manufacturing News

> Pfizer presence unmistakable in 1940s Brooklyn. News

> MA anticipates bioprocess job increase. Item

> Theravance MRSA drug a victim of Ben Venue shutdown. Report

> Issue separates bio, small molecule CMOs. News

> Online vaccines available from suspect sources. Article

And Finally... Flu vaccination rates are up this year, especially among children. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.